IS6590A - 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa - Google Patents

1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa

Info

Publication number
IS6590A
IS6590A IS6590A IS6590A IS6590A IS 6590 A IS6590 A IS 6590A IS 6590 A IS6590 A IS 6590A IS 6590 A IS6590 A IS 6590A IS 6590 A IS6590 A IS 6590A
Authority
IS
Iceland
Prior art keywords
fusion
farnesyl transferase
inhibits farnesyl
quinoline enantiomer
enantiomer
Prior art date
Application number
IS6590A
Other languages
English (en)
Other versions
IS2596B (is
Inventor
Gaston Venet Marc
René Angibaud Patrick
William End David
Original Assignee
Janssen Pharmaceutica N.V., Patent Department
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V., Patent Department filed Critical Janssen Pharmaceutica N.V., Patent Department
Publication of IS6590A publication Critical patent/IS6590A/is
Publication of IS2596B publication Critical patent/IS2596B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS6590A 2000-06-22 2002-10-25 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa IS2596B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number Publication Date
IS6590A true IS6590A (is) 2002-10-25
IS2596B IS2596B (is) 2010-03-15

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6590A IS2596B (is) 2000-06-22 2002-10-25 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa

Country Status (34)

Country Link
US (3) US20030114471A1 (is)
EP (1) EP1296984B1 (is)
JP (1) JP4919575B2 (is)
KR (2) KR100831940B1 (is)
CN (1) CN1207296C (is)
AR (1) AR030704A1 (is)
AT (1) ATE294804T1 (is)
AU (3) AU2001263962B2 (is)
BG (1) BG65894B1 (is)
BR (1) BRPI0111743B8 (is)
CA (1) CA2410232C (is)
CZ (1) CZ295278B6 (is)
DE (1) DE60110592T2 (is)
EA (1) EA005065B1 (is)
EE (1) EE04966B1 (is)
EG (1) EG24180A (is)
ES (1) ES2241830T3 (is)
HK (1) HK1058363A1 (is)
HR (1) HRP20020989B1 (is)
HU (1) HU229095B1 (is)
IL (2) IL153560A0 (is)
IS (1) IS2596B (is)
JO (1) JO2361B1 (is)
MX (1) MXPA02012845A (is)
MY (1) MY127734A (is)
NO (1) NO324494B1 (is)
NZ (1) NZ522481A (is)
PA (1) PA8519501A1 (is)
PL (1) PL209521B1 (is)
SA (1) SA01220349B1 (is)
SK (1) SK285699B6 (is)
UA (1) UA73572C2 (is)
WO (1) WO2001098302A1 (is)
ZA (1) ZA200210305B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
US7511138B2 (en) 2002-04-15 2009-03-31 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
SI3640345T1 (sl) 2015-08-17 2022-01-31 Kura Oncology, Inc. Postopki za zdravljenje rakavih pacientov z inhibitorji farneziltransferaze
EP3838275A1 (en) 2016-11-03 2021-06-23 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in methods of treating cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EP1162201B1 (en) * 1995-12-08 2006-03-29 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
EP0891334A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
NZ336233A (en) * 1997-04-25 2001-01-26 Janssen Pharmaceutica Nv Phenyl substituted quinazolines on 4-position and 2-quinazolinone moiety bearing a carbon or nitrogen-linked imidazolyl moiety
WO1998055124A1 (en) 1997-06-02 1998-12-10 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
DK1094839T3 (da) * 1998-07-06 2003-08-18 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
ES2212580T3 (es) 1998-07-06 2004-07-16 Janssen Pharmaceutica N.V. Inhibidores de la proteina farnesil-transferasa para el tratamiento de artropatias.
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
NZ509372A (en) * 1998-08-27 2003-08-29 Pfizer Prod Inc Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer)
CN1178938C (zh) * 1998-12-23 2004-12-08 詹森药业有限公司 1,2-稠合的喹啉衍生物
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
DE60020812T2 (de) * 1999-02-11 2006-05-04 Pfizer Products Inc., Groton Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
WO2002024687A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ES2313991T3 (es) 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.

Also Published As

Publication number Publication date
EA005065B1 (ru) 2004-10-28
PL358918A1 (en) 2004-08-23
AU2001263962B2 (en) 2006-07-20
AU6396201A (en) 2002-01-02
MXPA02012845A (es) 2003-05-15
EE04966B1 (et) 2008-02-15
US20070259902A1 (en) 2007-11-08
IS2596B (is) 2010-03-15
CZ2003114A3 (cs) 2003-05-14
CA2410232A1 (en) 2001-12-27
JO2361B1 (en) 2006-12-12
NZ522481A (en) 2004-09-24
EP1296984A1 (en) 2003-04-02
JP2004501153A (ja) 2004-01-15
EG24180A (en) 2008-09-28
EA200300048A1 (ru) 2003-04-24
NO20026032D0 (no) 2002-12-16
AU2006220405B2 (en) 2009-05-21
ES2241830T3 (es) 2005-11-01
WO2001098302A1 (en) 2001-12-27
NO324494B1 (no) 2007-10-29
CN1207296C (zh) 2005-06-22
HUP0300872A3 (en) 2004-11-29
KR100846370B1 (ko) 2008-07-15
EE200200695A (et) 2004-06-15
SA01220349B1 (ar) 2007-01-23
JP4919575B2 (ja) 2012-04-18
IL153560A0 (en) 2003-07-06
AU2006220405A1 (en) 2006-10-12
BR0111743A (pt) 2003-07-08
KR20070121847A (ko) 2007-12-27
BRPI0111743B1 (pt) 2019-03-26
KR100831940B1 (ko) 2008-05-23
ZA200210305B (en) 2004-03-19
HRP20020989B1 (en) 2011-05-31
US8318753B2 (en) 2012-11-27
EP1296984B1 (en) 2005-05-04
US8329714B2 (en) 2012-12-11
HUP0300872A2 (hu) 2003-07-28
CN1437601A (zh) 2003-08-20
DE60110592T2 (de) 2006-01-19
IL153560A (en) 2011-06-30
HU229095B1 (en) 2013-07-29
DE60110592D1 (de) 2005-06-09
ATE294804T1 (de) 2005-05-15
US20080114009A1 (en) 2008-05-15
US20030114471A1 (en) 2003-06-19
UA73572C2 (en) 2005-08-15
NO20026032L (no) 2002-12-16
CA2410232C (en) 2008-10-07
BG107310A (bg) 2003-07-31
BG65894B1 (bg) 2010-04-30
SK502003A3 (en) 2003-05-02
PL209521B1 (pl) 2011-09-30
PA8519501A1 (es) 2002-08-29
SK285699B6 (sk) 2007-06-07
HRP20020989A2 (en) 2005-02-28
BRPI0111743B8 (pt) 2021-05-25
HK1058363A1 (en) 2004-05-14
KR20030009463A (ko) 2003-01-29
CZ295278B6 (cs) 2005-06-15
MY127734A (en) 2006-12-29
AR030704A1 (es) 2003-09-03

Similar Documents

Publication Publication Date Title
RS51123B (sr) Aril fuzionisana azapoliciklična jedinjenja
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MXPA02005844A (es) Inhibidores de cinasas de proteina.
RS20110564A2 (en) ONE-DAY OXYCODON FORMULATIONS
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
IS6590A (is) 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
MXPA04005809A (es) Inhibidores de proteinas quinasas.
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
SE0102887D0 (sv) New formulation
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
HUP0401587A2 (hu) Új elnyújtott kibocsátású orális adagolási forma
TH59553B (th) 1,2-แอนเนเลเทด ควิโนลีน อิแนนซิโอเมอร์ ซึ่งมีฤทธิ์ยับยั้งฟาร์เนซิลทรานส์เฟอเรส